Steroid Conversion Calculator
Convert corticosteroid dosages between different medications based on anti-inflammatory potency equivalencies for oral and intravenous administration
Convert From
Convert To
Corticosteroid Equivalency Reference
| Steroid | Equivalent Dose (mg) | Anti-inflammatory Potency | Mineralocorticoid Activity | Duration (hours) |
|---|---|---|---|---|
| Cortisone | 25 | 0.8 | 0.8 | 8-12 |
| Hydrocortisone | 20 | 1.0 | 1.0 | 8-12 |
| Prednisone | 5 | 4.0 | 0.8 | 18-36 |
| Prednisolone | 5 | 4.0 | 0.8 | 18-36 |
| Methylprednisolone | 4 | 5.0 | 0.5 | 18-36 |
| Triamcinolone | 4 | 5.0 | 0 | 18-36 |
| Dexamethasone | 0.75 | 25-30 | 0 | 36-54 |
| Betamethasone | 0.6 | 25-30 | 0 | 36-54 |
Clinical Applications
Corticosteroids are synthetic analogues of cortisol with potent anti-inflammatory and immunosuppressive properties. These medications are widely used across medical specialties for various conditions including:
- Allergic and Respiratory: Asthma exacerbations, COPD, anaphylaxis, allergic rhinitis
- Rheumatologic: Rheumatoid arthritis, systemic lupus erythematosus, polymyalgia rheumatica
- Dermatologic: Severe eczema, pemphigus, contact dermatitis
- Hematologic: Hemolytic anemia, thrombocytopenic purpura, lymphomas
- Endocrine: Adrenal insufficiency, congenital adrenal hyperplasia
- Gastroenterologic: Inflammatory bowel disease, autoimmune hepatitis
- Neurologic: Multiple sclerosis, cerebral edema
Pharmacokinetic Properties
Corticosteroids are classified based on their duration of action and potency:
- Short-acting (8-12 hours): Cortisone, hydrocortisone – Higher mineralocorticoid activity
- Intermediate-acting (18-36 hours): Prednisone, prednisolone, methylprednisolone, triamcinolone
- Long-acting (36-54 hours): Dexamethasone, betamethasone – Minimal mineralocorticoid activity
The anti-inflammatory potency varies significantly between agents, with dexamethasone and betamethasone being 25-30 times more potent than hydrocortisone, while prednisone and prednisolone are approximately 4 times more potent.
Conversion Methodology
Steroid conversion calculations are based on comparative anti-inflammatory potency relative to hydrocortisone. The conversion formula utilized is:
Target dose = (Source dose × Source potency factor) ÷ Target potency factor
These equivalencies apply to both oral and intravenous administration routes. However, several factors may influence actual bioavailability and clinical effectiveness:
- Individual patient metabolism and liver function
- Concurrent medications affecting drug metabolism
- Disease state and inflammation severity
- Route of administration and absorption factors
Clinical Considerations
When converting between corticosteroids, healthcare providers should consider:
- Tapering Requirements: Long-term steroid users require gradual dose reduction to prevent adrenal insufficiency
- Timing: Short-acting steroids may require more frequent dosing compared to long-acting alternatives
- Side Effect Profile: Mineralocorticoid activity affects fluid retention and electrolyte balance
- Patient Monitoring: Regular assessment for hyperglycemia, hypertension, and other adverse effects
- Drug Interactions: Consider effects on hepatic enzyme induction and drug metabolism
Medical References
Hodgens A, Sharman T. Corticosteroids. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554612/
Chrousos GP, Kino T. Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress. 2007;10(2):213-9. doi: 10.1080/10253890701292119.
Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-23. doi: 10.1056/NEJMra050541.
Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med. 1977;63(2):200-7.
Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50(11):3408-17.